Moleculin Reports No Cardiotoxicity in 90-Patient Annamycin AML Safety Review
A pooled analysis of five clinical trials in 90 relapsed/refractory AML patients showed no clinically significant cardiotoxicity or decline in mean ejection fraction with Annamycin at cumulative anthracycline-equivalent doses exceeding conventional limits. These cardiac safety results may support Annamycin’s advancement into its pivotal Phase 3 MIRACLE study and enhance its potential as a differentiated anthracycline therapy in heavily pretreated AML.
1. Safety Findings from Pooled Trials
Moleculin’s pooled review of five completed clinical trials involving 90 relapsed/refractory AML patients demonstrated stable mean ejection fractions and no clinically significant left ventricular dysfunction, even at cumulative anthracycline-equivalent doses beyond conventional lifetime limits.
2. Overcoming Anthracycline Cardiotoxicity Barriers
These results suggest Annamycin can circumvent the principal cardiac toxicity barrier that restricts traditional anthracycline use, potentially enabling extended treatment options for heavily pretreated AML patients.
3. Next Steps: Phase 3 MIRACLE Trial and Positioning
Building on this cardiac safety profile, Moleculin is advancing the Phase 3 MIRACLE trial combining Annamycin with cytarabine and exploring broader clinical opportunities in AML and other oncology indications.